Rhizen Pharmaceuticals has started dosing in a phase I/Ib trial to assess the efficiency of PARP inhibitor (RP12146) in advanced cancer patients.
The Switzerland-based privately held, clinical-stage oncology & inflammation-focused biopharmaceutical company announced the first patient dosing in a Phase I/Ib study of their revolutionary PARP inhibitor (RP12146) in patients with advanced solid tumors.
Rhizen claims that RP12146 has identical preclinical efficacy to licensed PARP inhibitors, as well as enhanced preclinical safety, which it intends to demonstrate in the clinical study.
At Rhizen, RP12146 is part of a wider DDR platform contributing to the development of novel patented in-house combinations including the preclinical-stage (Polθ) inhibitor program.
The two-part multicenter Phase I/Ib study conducted in Europe is dedicated to first evaluate the safety, tolerability, maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D) of RP12146, and then to assess its anti-tumor activity in expansion cohorts with HRR mutation-enriched ES-SCLC, ovarian, and breast cancer patients.
RP12146 has demonstrated preclinical activity and effectiveness equivalent to the authorized PARP inhibitor Olaparib
RP12146 has demonstrated preclinical activity and effectiveness equivalent to the authorized PARP inhibitor Olaparib, as well as enhanced safety as observed in preclinical IND-enabling toxicity tests, which Rhizen believes will transfer into clinical trials. Rhizen also disclosed that their PARP program is part of a wider DNA Damage Response (DDR) platform endeavor, which includes a polymerase theta (Polθ) inhibitor product in the preclinical stage. Given the mechanistic synergy and potential across PARP resistant/refractory settings, Rhizen anticipates the platform to allow unique exclusive combinations of its PARP and (Polθ) assets.
Swaroop Vakkalanka, Founder & CEO of Rhizen Pharma stated:
“PARP inhibitors are a great success story in the DNA damage response area, but they are not without safety concerns that have limited realization of their full potential. Although our novel PARP inhibitor is competing in a crowded space, we expect its superior preclinical safety to translate into the clinic which will differentiate our program and allow us to extend its application beyond the current landscape of approved indications and combinations. Our PARP program is foundational for our DDR platform efforts and will be the backbone for several novel proprietary combinations that we hope to bring into development going forward.”
About Rhizen Pharmaceuticals AG.:
Rhizen Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development of breakthrough cancer and inflammatory treatments. Rhizen has built a wide pipeline of patented therapeutic candidates targeting a variety of malignancies and immune-related biological pathways since its founding in 2008.
With the development of Rhizen’s first PI3Kδ & CK1ε asset, Umbralisib, which has been successfully developed & commercialized in MZL & FL by the company’s licensing partner TG Therapeutics (TGTX) in the United States, Rhizen has demonstrated expertise in the PI3K modulator arena. Rhizen also has a robust oncology and inflammatory pipeline that spans discovery through phase II clinical development.
The headquarters of Rhizen are in Basel, Switzerland.
Please visit www.rhizen.com for further details.